VRCA - Verrica Pharmaceuticals Inc.
| Previous Close | 15.88 |
| Open | 15.97 |
| Bid | 14.50 x 1000 |
| Ask | 16.20 x 800 |
| Day's Range | 15.60 - 16.20 |
| 52 Week Range | 6.84 - 18.67 |
| Volume | 60,560 |
| Avg. Volume | 74,208 |
| Market Cap | 410.083M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.13 |
| Earnings Date | Nov 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.25 |
- GlobeNewswire
Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102
- Analysis suggested statistically significantly higher lesion clearance with VP-102 compared to vehicle in all regions of the body, including those deemed most sensitive - -.
- Zacks
Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study
Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.
- Insider Monkey
Is Verrica Pharmaceuticals Inc. (VRCA) A Good Stock To Buy?
Does Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend […]
- GlobeNewswire
Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company, today announced that its New Drug Application (NDA) for VP-102 (cantharidin 0.7% Topical Solution), a proprietary topical therapy for the treatment of molluscum contagiosum (molluscum), has been accepted for filing by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for this NDA is July 13, 2020.
- GlobeNewswire
Verrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2019 at 11:00 a.m. ET. Verrica is a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases.
- GlobeNewswire
Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn Oclassen
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), announces with deep sadness the passing of Glenn Oclassen, a valued member of the Company’s Board of Directors. Mr. Oclassen passed away on November 13, 2019. “Glenn was a renowned figure in the dermatology industry, and he brought a wealth of experience and energy, as he served our team with passion and commitment to advancing not only Verrica’s science and business, but the way in which the Company aimed to address a substantial unmet need, and serve its stakeholders with excellence,” said Paul B. Manning, Chairman, Board of Directors, Verrica Pharmaceuticals.
- GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results
-Submitted New Drug Application to U.S. Food and Drug Administration for VP-102 for the treatment of molluscum contagiosum -Presented three abstracts at the Fall Clinical.
- Simply Wall St.
We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced the presentation of positive data from three abstracts evaluating the efficacy and safety of VP-102 (cantharidin 0.7% Topical Solution), the Company’s lead product candidate for the treatment of molluscum contagiosum and common warts.
- GlobeNewswire
Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced it has appointed Eugene Scavola to the role of Executive Vice President, Technical Operations. An accomplished life sciences industry veteran, Mr. Scavola will spearhead Verrica’s Chemistry Manufacturing and Controls (CMC) functions. In this capacity, he will lead operational and technical aspects of product development, contract manufacturing, and analytical development activities for all Verrica product candidates.
- GlobeNewswire
Verrica Pharmaceuticals Announces Leadership Team Update
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that the Company has appointed A. Brian Davis as its new Chief Financial Officer (CFO). Mr. Davis replaces Chris Degnan, who is leaving the organization to pursue an opportunity in the oncology sector. Mr. Davis joins Verrica with nearly 15 years of experience as a CFO for publicly traded, commercial- and development-stage biopharmaceutical companies, and more than 25 years as a financial professional in the life sciences industry.
- Zacks
FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia
FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.
- Zacks
Will Verrica Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor Verrica Pharmaceuticals.
- Zacks
FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD
FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent patients.
- Zacks
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
- GlobeNewswire
Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for VP-102 (cantharidin 0.7% Topical Solution), a proprietary topical therapy, for the treatment of molluscum contagiosum (molluscum). No FDA-approved treatments are currently available for molluscum, a common, highly contagious skin disease affecting an estimated 6 million people in the United States, primarily children.
- Zacks
Small Drug Stock Outlook: Innovation Holds the Key to Growth
Small Drug Stock Outlook: Innovation Holds the Key to Growth
- Simply Wall St.
Have Insiders Been Buying Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- GlobeNewswire
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that Ted White, Verrica President and CEO, will present a business overview and review of the company’s pipeline programs at the H.C. Wainwright 21st Annual Global Investment Conference in New York, NY on Monday, September 9, 2019 at 3:00 p.m. ET. A live audio webcast of the event will be available in the Investors/Events & Presentations section of the Verrica website at http://www.verrica.com. Verrica is a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases.
- GlobeNewswire
Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial of VP-102 for the Treatment of External Genital Warts
Verrica Pharmaceuticals Inc. (Verrica) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that the first patient has been enrolled in the company’s Phase 2 ‘CARE’ clinical trial evaluating the optimal dose regimen, efficacy, safety and tolerability of VP-102, a novel topical therapy containing a solution of 0.7% cantharidin in a proprietary single-use applicator, in patients with external genital warts.
- Benzinga
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In The ...
- GlobeNewswire
Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts
Verrica Pharmaceuticals Inc. (Verrica) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced positive topline results from its COVE-1 Phase 2 open label clinical study of VP-102 for the treatment of verruca vulgaris, or common warts. COVE-1 included two cohorts that evaluated the safety and efficacy of VP-102, a novel topical therapy containing a solution of 0.7% cantharidin in a proprietary single-use applicator, in subjects with up to six warts.
- Simply Wall St.
What Type Of Shareholder Owns Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA)?
The big shareholder groups in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have power over the company. Institutions...
- GlobeNewswire
Verrica Pharmaceuticals Announces Participation in the Jefferies 2019 Healthcare Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that Ted White, Verrica President and CEO, will present a business overview of the company’s pipeline programs at the Jefferies 2019 Healthcare Conference in New York, NY on Tuesday, June 4, 2019 at 3:00 p.m. ET. A live audio webcast of the event will be available in the Investors/Events & Presentations section of the Verrica website at http://www.verrica.com/. Verrica is a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases.
- GlobeNewswire
Verrica Pharmaceuticals Reports First Quarter 2019 Financial Results
-Reported positive topline data from pivotal Phase 3 clinical trials of VP-102 for the treatment of molluscum contagiosum -Preparing to submit NDA in second half of 2019 WEST.
